2098
a Novel pre-treatment for the Prevention of Allergic reactions to medicines using a drug-free Carriers
Barenholz Yechezkel, HUJI, School of Medicine - IMRIC, Biochemistry and Molecular Biology
Background
-
Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles cause hypersensitivity reactions in up to 45% of patients,
which appear to be initiated by the complement system (C) of the immune system. -
Liposomes, Micelles,and other particulate drug carriers which do not carry C inhibitors on their surfaces will activate these hypersensitive reactions.
Our Innovation
a Novel treatment to prevent Allergic reactions to medicines by using a placebo drug-free Carrier, prior to the administration of particulate medicines
Applications for use:
Preventing an allergic reactions to medicines
Key Features
-
Technology specifically inhibits PCM-triggered C3a/C5a receptor-mediated complement activation-related pseudoallergy (CARPA) reactions
-
Toxicology tests for this technology are very simple
The Opportunity
Opportunity to incorporate new technology with minimal regulatory process
Researcher Information biochemistry.huji.ac.il/faculty_barenholz.asp, research.ekmd.huji.ac.il/researchers.asp?id=166, nanoscience.huji.ac.il/researchers/barenholz.htm